← Leaderboards
Christopher Bradley Doering
Expression Therapeutics
$9,776,945
Attributed
$18,762,216
Total exposure
23
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2006–25$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,762,216 · 23
By mechanism
R01$6,299,726 · 4
R44$4,469,084 · 3
R43$2,684,442 · 9
R42$2,586,823 · 2
U54$1,716,115 · 1
R21$420,750 · 1
Top collaborators
- H Trent Spencer23 shared
- Gabriela Denning12 shared
- Wilbur A Lam5 shared
- John S. Lollar4 shared
- Andres J Garcia2 shared
- Rebecca Diane Levit2 shared
- Brian G Petrich2 shared
- Lovick Edward Cannon1 shared
Most similar at Expression Therapeutics
Same institution · by research overlap
- Gabriela Denning$2,318,112
Others in their field
Top investigators on “Hemophilia A”
- Carol H Miao · Seattle Children'S Hospital$27,105,989
- Mark A Kay · Stanford University$24,062,703
- Roland W. Herzog · Indiana University Indianapolis$22,911,482
- Timothy Charles Nichols · University Of North Carolina Chapel Hill$19,506,050
- John S. Lollar · Emory University$17,412,316
- Mortimer Poncz · University Of Pennsylvania$14,969,626
Research focus
Hemophilia ADesignCellsFactor ViiiProductionBiomedical EngineeringSafetyRecombinantsGene TherapyTechnologyBaseFamily SuidaeTransgenesIn VivoEngineeringGene TransferCostPre-ClinicalLentivirus VectorProteinsBlood Coagulation FactorGeneticAnabolismHematopoietic
Grant awards (43)
Hydrogel Targeting of Organ Specific Gene Therapy$621,175
R01 · FY2025 · HL
Allogeneic cell and gene therapy for neuroendocrine tumors$400,000
R43 · FY2025 · CA
Hydrogel Targeting of Organ Specific Gene Therapy$635,300
R01 · FY2024 · HL
ADEPT-STAR therapy for high risk neuroblastoma$400,000
R43 · FY2023 · CA
Immunopharmacology of FVIII Bioengineering and Gene Therapy$343,223
U54 · FY2022 · HL · contact PI
A microfluidics-based paradigm for clinical lentivector gene transfer$500,223
R01 · FY2021 · HL
Immunopharmacology of FVIII Bioengineering and Gene Therapy$343,223
U54 · FY2021 · HL · contact PI
A microfluidics-based paradigm for clinical lentivector gene transfer$500,223
R01 · FY2020 · HL
Immunopharmacology of FVIII Bioengineering and Gene Therapy$343,223
U54 · FY2020 · HL · contact PI
Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic$752,051
R44 · FY2019 · HL
A microfluidics-based paradigm for clinical lentivector gene transfer$492,987
R01 · FY2019 · HL
Ancestral Sequence Reconstruction Engineering of Coagulation Factors$376,888
R01 · FY2019 · HL · contact PI
Immunopharmacology of FVIII Bioengineering and Gene Therapy$343,223
U54 · FY2019 · HL · contact PI
A Microscale Platform for Augmentation of Cell Transduction (MPACT) to Enhance Ex Vivo Gene Transfer$224,999
R43 · FY2019 · HL
Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic$747,641
R44 · FY2018 · HL
A microfluidics-based paradigm for clinical lentivector gene transfer$492,987
R01 · FY2018 · HL
Ancestral Sequence Reconstruction Engineering of Coagulation Factors$377,402
R01 · FY2018 · HL · contact PI
Immunopharmacology of FVIII Bioengineering and Gene Therapy$343,223
U54 · FY2018 · HL · contact PI
Ancestral Sequence Reconstruction Engineering of Coagulation Factors$391,891
R01 · FY2017 · HL · contact PI
Preclinical Evaluation of Ancestral Coagulation Factor VIII$224,976
R43 · FY2017 · HL
Bioengineering Factor VIII through Ancestral Reconstruction$385,276
R56 · FY2016 · HL · contact PI
Selection and preclinical validation of a lead candidate liver-directed AAV-FVIII expression cassette$224,223
R43 · FY2016 · HL
Bioengineered factor VIII gene therapy for hemophilia A$826,775
R44 · FY2015 · HL
Bioengineered Recombinant FVIII$673,613
R44 · FY2015 · HL
Bioengineered Recombinant FVIII$809,918
R44 · FY2014 · HL
Bioengineered factor VIII gene therapy for hemophilia A$659,086
R44 · FY2014 · HL
VLR-CART Cancer Immunotherapy$149,036
R43 · FY2014 · CA
Manufacturing Process Development for Bioengineered FVIII$386,432
R43 · FY2013 · HL
Hematopoietic gene therapy for hemophilia A$368,900
R01 · FY2013 · HL · contact PI
Hematopoietic gene therapy for hemophilia A$387,500
R01 · FY2012 · HL · contact PI
Bioengineered factor VIII gene therapy for hemophilia A$378,456
R43 · FY2012 · HL
Development of a novel production platform for complex recombinant biotherapeutic$296,320
R43 · FY2012 · HL
High Expression Recombinant Factor VIII$885,011
R42 · FY2011 · HL · contact PI
Hematopoietic gene therapy for hemophilia A$387,500
R01 · FY2011 · HL · contact PI
High Expression Recombinant Factor VIII$575,118
R42 · FY2010 · HL · contact PI
Ex Vivo Gene Therapy for Hemophilia A$420,475
R42 · FY2010 · HL · contact PI
Hematopoietic gene therapy for hemophilia A$387,500
R01 · FY2010 · HL · contact PI
Ex Vivo Gene Therapy for Hemophilia A$706,219
R42 · FY2009 · HL · contact PI
Hematopoietic gene therapy for hemophilia A$379,250
R01 · FY2009 · HL · contact PI
Bone Marrow-Derived Stem Cell Therapy of Hemophilia A$229,500
R21 · FY2008 · HL · contact PI
High Expression Recombinant Factor VIII$100,000
R41 · FY2008 · HL · contact PI
Bone Marrow-Derived Stem Cell Therapy of Hemophilia A$191,250
R21 · FY2007 · HL · contact PI
Ex Vivo Gene Therapy of Hemophilia A$100,000
R41 · FY2006 · HL · contact PI